Big leap innovation cannot be done in isolation. The Ksilink association was established in 2014 in Strasbourg, France. Its major objective is to build synergies enabling patient-based drug discovery. Today, Ksilink counts 12 members, 20 employees and runs its own platform for phenotypic screening and AI-based image analysis. Ksilink conducts a coherent pipeline of patient-based programs in the field of oncology, muscular and neurologic disorders. The non profit Association is financially supported by its members and the French initiative “Programme d’Investissements d’Avenir”.
A synergistic network in the heart of Europe
The 12 members of the Ksilink association are: